c-MYC is an important driver of ABC-type DLBCL[33]; therefore downregulation of c-MYC expression through activation of 4EBP1 may contribute to the effect of ibrutinib/AZD2014. This evidence concerns the gene EIF4EBP1 and diffuse large B-cell lymphoma.